GlaxoSmithKline settles ‘Avandia’ litigation with £1.6bn; Shares rise on ‘resolution’
GlaxoSmithKline, has announced it is settling the “substantial majority” of claims against its ‘thiazolidinedione’ Avandia which was found to cause death in ‘heart failure’ patients after it was released to market.